For a brief, glittering moment, ADMA Biologics looked like one of biotech's quietly brilliant success stories. The Boca Raton-based plasma products company reported full-year 2025 revenue of $510.2 million — a 20% year-over-year gain — driven largely by ASCENIV, its FDA-approved immune globulin therapy for patients with primary humoral immunodeficiency. On paper, everything tracked. In practice, according to a securities fraud class action now moving through federal court, the story was manufactured.

On March 24, 2026, short-selling research firm Culper Research published a report with a blunt title: "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported." The document alleged that ADMA had induced at least one of its distributors to take on excess ASCENIV inventory by offering rebates and extended payment terms — a classic channel-stuffing maneuver that books revenue the moment product ships to a middleman, regardless of whether any patient ever receives it. Culper's core claim: strip out the inflated distributor loading, and ADMA's 2025 growth was actually negative three percent, not positive twenty.

The market's verdict was instantaneous and brutal. On the day the report dropped, ADMA's share price fell $2.26, or 16.6%, from $13.59 to $11.33. It didn't recover. Over the following trading sessions, cumulative losses pushed the total decline to roughly 29% from pre-report levels, erasing hundreds of millions of dollars in market capitalization and leaving a trail of retail and institutional shareholders badly underwater.

The company fired back quickly. ADMA's investor relations team published a statement characterizing the Culper report as a misleading attack from a firm that had already taken a short position in the stock — standard operating procedure for short-sellers, but also a standard deflection that does not, by itself, address the underlying accounting questions. ADMA did not, in its public response, produce audited distributor-level sell-through data or formally rebut the specific allegation about extended payment terms and rebate agreements. The company's 2025 annual figures had been officially reported to the SEC, but the integrity of how those revenues were recognized is precisely what is now under judicial scrutiny.

The class action, captioned *Mazzarino v. ADMA Biologics*, covers all investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 — a window that encompasses nearly the entire run-up period during which management repeatedly told shareholders the growth was organic and sustainable. The lawsuit alleges that during this period ADMA and certain senior executives made materially false or misleading statements about the company's financial condition, revenue recognition practices, inventory distribution strategy, and overall business health, in potential violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

Channel stuffing, to be clear about what is alleged here: it is not a gray area in securities law. When a company recognizes revenue by pushing product onto distributors through artificially sweetened terms — knowing that the distributor cannot move the inventory at normal velocity — and simultaneously represents to the investing public that demand is robust and organic, that is the textbook definition of misleading revenue inflation. Whether ADMA crossed that line is for the court to determine. What is not in dispute is that a 29% stock collapse followed a specific, documented allegation about its distribution practices, and that the company's rebuttal was notably short on the kind of verifiable detail that would settle the question.

The August 10, 2026 deadline is a procedural milestone under the Private Securities Litigation Reform Act of 1995: it is the last day on which an eligible investor can petition the court to be appointed lead plaintiff — the shareholder who will effectively guide the litigation strategy. The PSLRA was designed to put large, sophisticated institutional investors in the driver's seat of class actions rather than the plaintiff's law firms, whose business model depends on generating fee volume. Investors with losses exceeding $100,000 are the practical target audience for lead-plaintiff motions; smaller shareholders are still class members and still eligible for any eventual recovery, but they have no control over how the case is litigated.

None of this means ADMA is guilty of securities fraud. Short-sellers have financial incentives to destroy the stocks they bet against, and Culper Research is not a neutral party. The allegations have not been proven, no government enforcement action has been announced, and ADMA has contested the characterization of its revenue practices. What has been proven is that investors bought shares at prices that reflected a 20% growth narrative, the narrative was then publicly challenged with specific factual allegations, and the stock fell nearly a third before anyone in an official capacity had a chance to rule on who was right. That gap — between what was sold to the market and what Culper claims was actually happening in the distribution channel — is the wound at the center of this case, and it will not close quietly.